Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( which provides development and biomanufacturing services for both Peregrine and outside customers.
Company Growth (employees)
Tustin, US
Size (employees)
281 (est)+34%
Peregrine Pharmaceuticals was founded in 1981 and is headquartered in Tustin, US

Peregrine Pharmaceuticals Office Locations

Peregrine Pharmaceuticals has office in Tustin
Tustin, US

Peregrine Pharmaceuticals Metrics

Peregrine Pharmaceuticals Summary

Market capitalization

$192.1 m

Closing share price

Peregrine Pharmaceuticals's current market capitalization is $192.1 m.

Peregrine Pharmaceuticals Financials

Peregrine Pharmaceuticals's revenue is $44.7 m in FY, 2016 which is a 66.9% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$22.4 m$26.8 m$44.7 m

Revenue growth, %


Gross profit

$9.2 m$11.2 m$21.4 m

Operating expense total

$26.5 m$39.3 m$35 m


($35.7 m)($50.5 m)($56.4 m)

Net Income

($35.4 m)($50.4 m)($55.7 m)

Operating cash flow

$42.3 m($9.5 m)($6.6 m)

Peregrine Pharmaceuticals Market Value History

Peregrine Pharmaceuticals Company Life

You may also be interested in